Your browser is no longer supported. Please, upgrade your browser.
HCM [NASD]
Hutchison China MediTech Limited
Index- P/E- EPS (ttm)-0.82 Insider Own6.26% Shs Outstand145.54M Perf Week-8.10%
Market Cap4.92B Forward P/E- EPS next Y-0.92 Insider Trans0.00% Shs Float63.90M Perf Month16.02%
Income- PEG- EPS next Q- Inst Own33.78% Short Float1.77% Perf Quarter6.92%
Sales209.46M P/S23.50 EPS this Y-8.70% Inst Trans- Short Ratio7.45 Perf Half Y26.29%
Book/sh2.49 P/B13.58 EPS next Y-5.70% ROA- Target Price38.16 Perf Year16.62%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range14.74 - 37.00 Perf YTD5.62%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-8.59% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low129.44% ATR1.50
Employees853 Current Ratio- Sales Q/Q6.70% Oper. Margin- RSI (14)55.38 Volatility4.79% 5.00%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.13 Prev Close35.00
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume152.15K Price33.82
Recom1.70 SMA205.18% SMA508.38% SMA20019.72% Volume172,015 Change-3.37%
Oct-02-20Initiated Deutsche Bank Buy $40
Mar-13-20Initiated Cantor Fitzgerald Overweight
Feb-20-20Initiated Goldman Buy
Nov-19-19Initiated CLSA Buy
Oct-23-19Reiterated BofA/Merrill Buy $35 → $29
Jul-05-19Initiated Macquarie Outperform
Jan-14-21 05:00AM  
Jan-10-21 08:00PM  
Dec-30-20 07:00AM  
Dec-28-20 01:25PM  
Dec-22-20 07:24PM  
02:00AM  
Nov-30-20 10:35PM  
Nov-17-20 02:00AM  
Nov-05-20 04:00AM  
Oct-30-20 08:00AM  
Oct-20-20 05:03AM  
Sep-20-20 08:25AM  
Sep-17-20 06:45AM  
Sep-04-20 02:00AM  
Sep-03-20 02:04AM  
Aug-24-20 02:00AM  
Aug-10-20 09:10AM  
02:00AM  
Jul-30-20 11:01PM  
08:47AM  
Jul-28-20 02:00AM  
02:00AM  
Jul-24-20 02:00AM  
Jul-22-20 03:11AM  
Jul-06-20 12:55PM  
Jun-26-20 02:00AM  
Jun-25-20 08:26AM  
02:15AM  
Jun-18-20 03:15AM  
Jun-12-20 01:03PM  
Jun-09-20 02:00AM  
Jun-04-20 02:00AM  
Jun-01-20 02:00AM  
May-29-20 08:00AM  
02:00AM  
May-26-20 04:04AM  
02:00AM  
May-14-20 02:00AM  
May-11-20 12:17AM  
May-08-20 04:12AM  
Apr-23-20 03:12AM  
Apr-22-20 08:15AM  
04:00AM  
Apr-17-20 07:35AM  
02:00AM  
Apr-07-20 03:32PM  
Mar-31-20 02:46AM  
Mar-26-20 08:35AM  
08:35AM  
Mar-16-20 08:35AM  
Mar-10-20 08:35AM  
Mar-05-20 12:00PM  
Mar-03-20 10:26AM  
Feb-25-20 02:15AM  
Feb-12-20 08:00PM  
12:27PM  
Feb-10-20 05:08AM  
Feb-06-20 02:58AM  
Jan-31-20 02:19AM  
Jan-23-20 11:52PM  
03:06AM  
Jan-21-20 06:46PM  
08:00AM  
Jan-20-20 06:17AM  
06:08AM  
Jan-16-20 12:00PM  
Jan-13-20 02:00AM  
Jan-06-20 02:50AM  
Dec-20-19 02:05AM  
Dec-14-19 06:39PM  
Dec-09-19 06:16AM  
Nov-29-19 07:35AM  
Nov-28-19 02:15AM  
Nov-25-19 02:15AM  
Nov-22-19 08:00PM  
Nov-15-19 08:35AM  
01:01AM  
Nov-11-19 02:15AM  
Nov-06-19 08:35AM  
08:35AM  
Oct-29-19 01:58PM  
Oct-17-19 02:45AM  
Oct-10-19 07:45AM  
04:15AM  
Oct-04-19 02:39AM  
Oct-01-19 03:35AM  
Sep-30-19 09:12AM  
09:10AM  
07:16AM  
Sep-29-19 11:00AM  
Sep-25-19 02:15AM  
Sep-18-19 02:15AM  
Sep-16-19 09:39AM  
Sep-03-19 02:46AM  
02:25AM  
Aug-26-19 12:54AM  
Aug-23-19 02:15AM  
Aug-14-19 10:15AM  
Jul-30-19 02:41PM  
04:43AM  
Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China. It operates through Innovation Platform and Commercial Platform segments. The company provides research and development services; and develops, manufactures, distributes, and markets prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical stage drugs include Savolitinib, an inhibitor for the treatment of non-small cell lung cancer, papillary renal cell carcinoma, colorectal cancer, gastric cancer, and prostate cancer; and Fruquintinib, an inhibitor for the treatment of colorectal cancer and solid tumors. The company is also developing Surufatinib, an inhibitor for the treatment of pancreatic neuroendocrine tumors and solid tumors; HMPL-523, an inhibitor for the treatment of indolent non-Hodgkin's lymphoma; and HMPL-689 for the treatment of indolent non-Hodgkin's lymphoma. In addition, it engages in the development of HMPL-453, an inhibitor for the potential treatment of solid tumors; HMPL-306, a molecule dual-inhibitor of isocitrate dehydrogenase 1 and 2 for the treatment of hematological malignancies, gliomas, and solid tumors; and clinical-stage EGFR inhibitors, such as Epitinib and theliatinib. Hutchison China MediTech Limited has a clinical collaboration agreement with BeiGene, Ltd. to evaluate the safety and efficacy of combining surufatinib and fruquintinib with BeiGenes anti-PD-1 antibody tislelizumab for the treatment of various solid tumor cancers. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.